Can a patient take ropinirole twice daily for restless legs syndrome?

Can Ropinirole Be Taken Twice Daily for Restless Legs Syndrome?

Although ropinirole can be dosed twice daily for RLS according to FDA labeling, the 2025 American Academy of Sleep Medicine guideline conditionally recommends against using ropinirole (or any dopamine agonist) as standard therapy due to a 7–10% annual risk of augmentation—an iatrogenic worsening of RLS symptoms that escalates with treatment duration. 1

Current Guideline Position on Dopamine Agonists

• The 2025 AASM guideline represents a major paradigm shift away from dopamine agonists (pramipexole, ropinirole, rotigotine) as first-line RLS therapy, citing moderate-certainty evidence that augmentation risk outweighs short-term efficacy benefits. 1

• Ropinirole should be reserved only for short-term bridge therapy when patients explicitly accept augmentation risk and prioritize rapid symptom relief over long-term safety. 1

• Augmentation risk increases with duration of dopaminergic therapy, even at low doses, making chronic twice-daily dosing particularly problematic. 1

FDA-Approved Dosing (When Ropinirole Is Used)

• For RLS, the FDA label specifies once-daily dosing 1–3 hours before bedtime as the standard regimen, starting at 0.25 mg and titrating up to a maximum of 4 mg daily. 2

• Twice-daily dosing is described in one clinical trial where patients with early evening symptom onset received equally divided doses: the first dose 1 hour before usual symptom onset and the second dose 3–8 hours after the first, with total daily doses ranging from 0.5–6.0 mg. 3

• The FDA label does not explicitly endorse twice-daily dosing as standard practice for RLS; the approved regimen remains once daily at bedtime. 2

Evidence for Twice-Daily Dosing

• A 12-week randomized controlled trial (n=359) demonstrated that twice-daily ropinirole significantly improved IRLS scores compared to placebo at all time points from day 3 through week 12 (P<0.001), with 68–75% of patients reporting "much" or "very much" improvement versus 51% on placebo. 3

• However, this trial predates the 2025 guideline's recognition of augmentation as a critical safety concern, and the study did not assess long-term augmentation rates beyond 12 weeks. 3

Recommended First-Line Alternatives

• Gabapentinoids (gabapentin enacarbil, gabapentin, or pregabalin) are the only first-line pharmacologic agents for RLS, with strong recommendations and moderate certainty of benefit; approximately 70% of treated patients achieve much or very much improved symptoms versus 40% with placebo. 1, 4

• Iron repletion with IV ferric carboxymaltose 1000 mg is strongly recommended when serum ferritin ≤100 ng/mL or transferrin saturation <20%, as correcting iron deficiency may eliminate the need for chronic medication. 1

• Oral ferrous sulfate 325–650 mg daily or every other day is a conditional alternative when IV access is limited. 1

Critical Safety Concerns with Ropinirole

• Augmentation manifests as earlier daily symptom onset (afternoon instead of evening), shorter latency to symptoms when at rest, spread to arms or trunk, and increased intensity requiring dose escalation. 1, 2

• Do not increase ropinirole doses in response to worsening symptoms, as this likely reflects augmentation rather than tolerance and will exacerbate the problem. 1

• Orthostatic hypotension is a documented risk, particularly in elderly patients, and can trigger prescribing cascades with additional medications (e.g., midodrine, compression stockings) to manage iatrogenic side effects. 2, 5

• Sudden sleep attacks, impulse control disorders (pathological gambling, hypersexuality, compulsive spending), and withdrawal symptoms (insomnia, anxiety, depression, pain) are additional FDA-labeled risks. 2

Treatment Algorithm for RLS

1. Check serum ferritin and transferrin saturation after 24-hour avoidance of iron supplements; initiate IV ferric carboxymaltose 1000 mg if ferritin ≤100 ng/mL or TSAT <20%. 1

2. Discontinue RLS-exacerbating medications (serotonergic antidepressants, dopamine antagonists, centrally acting antihistamines) and minimize alcohol and caffeine. 1

3. Start a gabapentinoid (gabapentin enacarbil, gabapentin, or pregabalin) as first-line pharmacologic therapy. 1

4. If inadequate response after 4–6 weeks of optimized gabapentinoid therapy, add or switch to extended-release oxycodone (5–10 mg daily) rather than a dopamine agonist. 1

5. Reserve ropinirole only for short-term use (weeks to months) when patients explicitly accept augmentation risk and rapid symptom control is prioritized; plan transition to first-line therapy. 1

6. Monitor every visit for augmentation red flags: earlier symptom onset, shorter latency at rest, symptom spread, or increased intensity. 1, 2

Special Population Considerations

• In end-stage renal disease, ropinirole is contraindicated per the 2025 AASM guideline; gabapentin with renally-adjusted dosing (100–300 mg post-dialysis) is the preferred agent. 1

• The maximum recommended dose in dialysis patients is 3 mg/day (versus 4 mg/day in non-dialysis RLS), with no supplemental doses required after dialysis. 2

Bottom Line

Twice-daily ropinirole dosing is technically feasible based on one clinical trial and may provide symptom coverage for patients with early evening onset, but the 2025 AASM guideline's conditional recommendation against dopamine agonists as standard therapy—due to escalating augmentation risk—makes gabapentinoids and iron optimization the preferred initial approach. 1, 3 If ropinirole is used, once-daily bedtime dosing per FDA labeling minimizes total daily exposure and augmentation risk compared to twice-daily regimens. 2